CRISPR Stock: On Track for Clinical Trials and FDA Approved Therapy
Wednesday, 15 May 2024, 15:11
CRISPR Stock: A Closer Look
Is CRISPR Therapeutics (NASDAQ: CRSP) on the path to success amid recent financial challenges?
Revenue Plunge and Recovery
- Revenue: Dropped 99.5% year over year, impacting per-share losses.
- Analyst Prediction: Target price set at $95 by Oppenheimer's Jay Olson.
Therapeutic Advancements
- CTX112 Trials: Gene-editing treatment for lupus and ongoing cancer trials.
- Casgevy Approval: FDA nod for sickle cell anemia therapy, promising revenue share with Vertex Pharmaceuticals.
CRISPR's financial stability and growth potential may influence future stock performance.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.